X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GMI-1687 is a highly potent E-selectin antagonist that is bioavailable after subcutaneous administration. It is under phase 1 clinical development for the treatment of sickle cell disease.
Lead Product(s): Uproleselan
Therapeutic Area: Hematology Product Name: GMI-1687
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2024
Details:
GMI-1271 (uproleselan) is designed to bind to E-selection and block the normal processes controlled by E-selectin. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect via NF-kB signaling.
Lead Product(s): Uproleselan,Mitoxantrone,Etoposide
Therapeutic Area: Oncology Product Name: GMI-1271
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2023
Details:
Completion of enrollment of GMI-1271 (Uproleselan), sets the stage for planned interim analysis evaluating potential for regulatory filings, improves overall survival in newly diagnosed patients 60 years or older with acute myeloid leukemia.
Lead Product(s): Uproleselan,Daunorubicin,Cytarabine
Therapeutic Area: Oncology Product Name: GMI-1271
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021
Details:
Uproleselan is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment.
Lead Product(s): Uproleselan
Therapeutic Area: Oncology Product Name: GMI-1271
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2021
Details:
The combination of uproleselan with a standard salvage regimen of mitoxantrone, etoposide and cytarabine (MEC) demonstrated a substantial improvement in both response rate and survival in relapsed/refractory AML patients.
Lead Product(s): Uproleselan,Cladribine,Cytarabine
Therapeutic Area: Oncology Product Name: GMI-1271
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2021
Details:
The study is designed to evaluate both the safety and tolerability of the combination therapy, as well as to identify a recommended Phase 2 dose of the uproleselan triple combination approach in patients with ts-AML.
Lead Product(s): Uproleselan,Cladribine,Cytarabine
Therapeutic Area: Oncology Product Name: GMI-1271
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2021
Details:
The study demonstrates that GMI-1757 significantly improved anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model.
Lead Product(s): GMI-1757
Therapeutic Area: Oncology Product Name: GMI-1757
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2021
Details:
Preclinical data highlight anti-tumor activity in pancreatic cancer model with GMI-1757, a novel galectin-3 antagonist. GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4.
Lead Product(s): GMI-1359
Therapeutic Area: Oncology Product Name: GMI-1359
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Details:
The Phase 1 clinical trial in China is a part of the Phase 1 and Phase 3 bridging clinical study of APL-106 in combination with chemotherapy in adults with relapsed or refractory AML.
Lead Product(s): Uproleselan
Therapeutic Area: Oncology Product Name: APL-106
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Apollomics Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
Uproleselan, when added to a combination therapy of venetoclax, was shown to break chemoresistance by dramatically and significantly reducing tumor burden as detected by circulating human AML cells after three weeks of treatment, and by significantly increasing survival rate.
Lead Product(s): Uproleselan,Venetoclax,Hypomethylating agent
Therapeutic Area: Oncology Product Name: GMI-1271
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
